Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - ARK Genomic Revolution ETF (BATS:ARKG)
ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.
How this was made
The 30-second read
Why it matters
The trades provide fresh capital to selected companies and illustrate ARKG's active management style versus broader biotech ETFs.
Market read
The disclosed trades may influence short‑term price action in the highlighted biotech stocks and affect ARKG's NAV composition.
What to watch
Liquidity constraints of small‑cap biotech may limit price gains despite ETF buying.
Background
Cathie Wood's ARK Genomic Revolution ETF disclosed recent portfolio changes, adding and trimming biotech positions.
Ticker impact
ARKG bought about $4.5 million of Ionis Pharmaceuticals.
Potential short‑term rally.
Purchase size relative to float is notable.
ARKG bought nearly $3 million of Veracyte.
Likely modest upside.
ETF buying adds credibility to the company's growth story.
ARKG bought roughly $2.6 million of Beam Therapeutics.
Short‑term price lift expected.
Fund purchase size is material for a small‑cap biotech.
ARKG bought about $1.9 million of Scribe Therapeutics.
Potential upward pressure.
Early‑stage company receiving significant ETF backing.
ARKG sold more than $2.5 million of 10x Genomics.
Minor downside pressure.
Sale size is modest relative to market cap.
Market effects
Highlights continued investor interest in genomics and gene‑editing biotech.
U.S. biotech sector may see modest uplift.
Signals broader confidence in precision‑medicine themes.
Counterpoint
Fund concentration could amplify downside if sector sentiment turns negative.
Key entities
- PersonCathie Wood
Founder of ARK Invest, driving the fund's investment decisions.
- ETFARK Genomic Revolution ETF
Actively managed fund focusing on genomics and precision medicine.
